- The news is real, the "cure" isn't. For the first time, several drugs are regrowing measurable hair in placebo-controlled trials — and one is designed to wake dormant follicles rather than just slow loss. None has been tested on men who've been bald for years
- Closest to pharmacies: clascoterone scalp solution (two phase 3 trials in 1,465 men; US filing planned for Q1 2027, so a decision likely in 2028) and a purpose-built extended-release oral minoxidil (+30 hairs/cm² vs +7 on placebo at six months; second pivotal trial reads out late 2026)
- The regenerative bets: PP405 (Pelage, Los Angeles) — 31% of men with more advanced loss gained over 20% hair density in eight weeks vs 0% on placebo, in a small subgroup; a 600-man trial is registered. Rubedo's RLS-1496 — the one in the headlines this month — has only been tested on follicles in a dish so far
- Asia is moving: China's Kintor has a positive phase 3 for a DHT-blocking lotion; Japan already offers a cell therapy from your own follicle cells; Korea has a cell-injection trial running
- Don't wait for 2028. Finasteride and minoxidil still work: at five years, 48% of men on finasteride looked better and 42% unchanged — vs 75% worse on placebo. What you keep now is what the new drugs will have to work with
If you've read a hair-loss headline this month, it probably promised the end of baldness. On September 16, Rubedo Life Sciences, a California biotech, announced a clinical study of a drug that clears "zombie" cells from ageing follicles. Last October, a Los Angeles company called Pelage raised $120 million on the back of a gel it says regrew hair from follicles that had stopped producing it. In China, a DHT-blocking lotion just passed a phase 3 trial. A new oral minoxidil built for hair, not blood pressure, is due to report its final big trial before the year is out.
Some of this is the most genuinely new science hair loss has seen since finasteride in the 1990s. Some of it is a press release. This article sorts one from the other. We went through every candidate we could find in human trials — the company announcements, the trial registrations, and the published papers — and checked the numbers against the source. For each one you'll get what it does, what the trial actually measured, what the headline left out, and when you could realistically get it. Then, because the answer to "when" is mostly "not this year," what works today.
Every hair-loss drug worth knowing about, and how far along it is
Stage as of September 2026, from company releases and ClinicalTrials.gov. "Filed" = submitted to a regulator. Timelines are the companies' own, and in this field they slip — two of the programmes above have already moved theirs back.
One Hormone, One Receptor, and a Shrinking Follicle
Evidence: Strong — decades of genetics, hormone and drug studiesYou can't judge the new drugs without knowing what they're aiming at, and the target has been clear for a long time. Male-pattern hair loss — androgenetic alopecia, in the trials — is driven by dihydrotestosterone, DHT. An enzyme in the scalp called type 2 5-alpha-reductase converts testosterone into DHT, and DHT binds androgen receptors in genetically sensitive follicles on the crown and temples (Ntshingila, JAAD International 2023). The evidence that DHT is the key hormone comes from nature's own experiments: men castrated before puberty don't go bald, and neither do men born without working type 2 5-alpha-reductase (Kaufman, Molecular and Cellular Endocrinology 2002).
What DHT does is subtle. It doesn't kill follicles; it shrinks them. Each hair grows through a cycle — a long growth phase (anagen), a short transition, a resting phase, then shedding — and in a sensitive follicle, every pass through the cycle gets a shorter growth phase and produces a thinner, shorter hair. Over years, thick "terminal" hairs become the fine, colourless "vellus" hairs you see on a bald scalp in bright light. This is called miniaturisation, and it's the single most important idea in this article, for two reasons. First, it's why the drugs that exist work best early: a follicle that's still producing something can be pushed back up. Second, it's the thing the regenerative drugs are betting on — that a miniaturised follicle, or even a dormant one, still has stem cells that can be switched back on.
From testosterone to a bald crown — and the seven places to intervene
Swipe the diagram →
Schematic, not to scale. Numbers 1–3 act on the hormone pathway or the hair cycle; 4–7 are the newer "regenerative" approaches.
Once you see it laid out like that, the whole pipeline makes sense. The drugs that already exist attack steps 1 and 3. The late-stage newcomers mostly attack step 2 — the same hormone pathway, but locally, so the scalp is protected without lowering DHT in the rest of the body, which is the source of finasteride's side-effect worries. The genuinely new ideas are steps 4 through 7, and they're earlier, riskier and more exciting, because they're the only ones with a plausible route to bringing back hair that's already gone rather than defending what's left.
Three Drugs That Could Reach You by 2028
Evidence: Moderate — large trials, but most results only in company releases so farA word on the numbers before we start. Almost every hair-loss trial measures the same thing: the change in target-area hair count — the number of non-vellus hairs in a small tattooed or marked patch of scalp, photographed at the start and again months later, compared with people using a placebo. It's objective and it's what regulators want, so when you see "hairs per cm²" below, that's what it means. The catch is that for the most advanced candidates, the numbers so far come from company announcements rather than peer-reviewed papers, and one company in particular has been selective about which numbers it shares. We flag it where that's the case.
1. Clascoterone 5% solution — the scalp-only DHT blocker
Clascoterone blocks the androgen receptor — step 2 in the diagram — and it's designed to do it only where you put it. That's the whole pitch: protect the follicle from DHT without lowering DHT in the rest of the body. The molecule isn't new; it's already FDA-approved as a 1% cream for acne. For hair, Cosmo Pharmaceuticals ran two phase 3 trials, SCALP 1 and SCALP 2, in 1,465 men at 51 sites across the US and Europe (NCT05910450, NCT05914805), with men randomised two-to-one to the solution or a placebo solution twice daily for six months.
Both trials hit statistical significance on hair count. In Cosmo's December 2025 announcement, one showed what the company called a "5.39x (539 percent) relative improvement" in target-area hair count versus placebo, the other a "1.68x (168 percent)" improvement. Each trial also had a second, patient-rated primary endpoint — do you think your hair looks better? — and that one reached significance in one trial and "showed a positive trend" in the other, which is company language for "missed." Twelve-month data in April 2026 added a useful finding: among men who had responded by six months, those who stayed on it for the full year had 2.39 times the hair-count gain of those switched to placebo for the second half. Cosmo reported no significant hormonal side effects, without giving rates.
When: The December 2025 headline said US and EU submissions were "underway." They weren't — by the company's July 2026 report, the US filing is planned for the first quarter of 2027 and Europe's for the second. A standard FDA review takes around a year from filing, which puts a realistic US decision in 2028. For a man worried about finasteride's side effects, this is the one to watch.
2. VDPHL01 — minoxidil, rebuilt as a hair pill
This one isn't a new drug; it's a new version of an old one. Low-dose oral minoxidil — blood-pressure tablets, cut into quarters — has become a popular off-label hair treatment in the past few years, because it seems to work about as well as the liquid and nobody has to rub anything on their head twice a day. Its safety at low doses is reasonable: in a Spanish study of 1,404 patients, the commonest side effect was unwanted body and facial hair (15.1%), lightheadedness occurred in 1.7% and fluid retention in 1.3%, and only 1.7% stopped because of side effects (Vañó-Galván, JAAD 2021). But it has never been formally tested, dosed or approved for hair.
Veradermics, a Connecticut company that listed on the New York Stock Exchange this year, built an extended-release tablet designed to avoid the peaks in blood levels that the company links to minoxidil's heart and blood-pressure effects. Its first large trial, Study 302, gave 519 participants the pill once or twice a day, or placebo, for six months (company filing, April 2026). Target-area hair count rose by 30.3 hairs/cm² once daily and 33.0 twice daily, against 7.3 on placebo (both p<0.0001), with significant growth from month two. On the question that matters to the person in the mirror, 48.4% (once daily) and 62.9% (twice daily) rated their hair improved or much improved, against 13.4% on placebo. The company reported no treatment-related serious side effects and no cardiac events of special interest — but hasn't yet published the rates of body-hair growth, fluid retention or heart-rate changes, which are exactly the numbers a doctor will want.
When: A second pivotal trial of 536 men, Study 304, is due to report in the second half of 2026. Veradermics hasn't given a filing date.
3. Pyrilutamide (KX-826) — China's second attempt
Kintor Pharmaceutical of Suzhou has been developing a topical androgen-receptor blocker for years, and its history is a good lesson in why "phase 3" isn't the same as "works." Its first phase 3, in 740 men using a 0.5% lotion, was announced in November 2023: hair improved from where men started, but not significantly more than on placebo. The trial failed.
The company went back with a stronger dose. In March 2026 it reported a new phase 3 stage — 666 men at 26 Chinese centres for 24 weeks (Kintor, March 2026). Hair count rose by 15.33 hairs/cm² on the 1.0% lotion and 14.46 on 0.5%, against 4.68 on placebo — a placebo-adjusted gain of about 10 hairs/cm², highly significant, with no drug-related serious side effects. Kintor says it will file for approval in China with the 1.0% strength. There's no US phase 3; a 123-man US phase 2 in 2023 met its primary endpoint but gave no placebo-adjusted figure.
Extra hairs per cm² over placebo, in trials that reported it
Change in target-area hair count on the drug minus the change on placebo, from company releases. Different trials, lengths and men — read this as "what each has shown so far," not a head-to-head ranking. Clascoterone, PP405 and ET-02 haven't released comparable hair counts, so they can't be charted.
Waking Follicles Up, Not Just Protecting Them
Evidence: Early — small trials, lab and animal dataEverything in part two works on the hormone pathway or the growth cycle. That's valuable, but it has a ceiling: it rescues follicles that are shrinking. The companies in this section are chasing something bigger — follicles that have stopped producing visible hair altogether. If one of them works, it's the first real change in what's possible since the 1990s. None has proven it yet.
PP405 — the stem-cell switch from UCLA
The science behind PP405 started in mice. In 2017, a UCLA team showed that hair follicle stem cells switch into growth mode when they ramp up production of lactate, and that blocking a molecule called the mitochondrial pyruvate carrier forced them to do exactly that — and made resting mouse follicles start growing hair (Flores, Nature Cell Biology 2017). Pelage Pharmaceuticals licensed the chemistry, developed a gel, and in June 2025 reported its first human trial (Pelage, June 2025).
The trial was small and short: 78 men and women with pattern hair loss, randomised to the gel or placebo, applied once a day for just four weeks (NCT06393452). Its official goals were safety and whether any drug got into the bloodstream — it passed both, and none was detected in the blood. The headline number came from a subgroup: "in men with a higher degree of hair loss, 31% of those treated with PP405 exhibited a greater than 20% increase in hair density" at week eight, four weeks after stopping treatment, "compared to 0%" on placebo. At the American Academy of Dermatology meeting in March 2026, the company added that new terminal hairs had grown from previously dormant follicles — the claim that makes this different from everything in part two.
When: In October 2025 Pelage raised $120 million to fund late-stage trials. The first, called AWAKEN, was posted to the US trial registry this month (NCT07819435): about 600 men with moderate-to-advanced loss (Norwood IV–V), gel against placebo for 24 weeks and then an extension to a full year, with the main hair-count result expected around December 2027. It isn't recruiting yet. Even if everything goes right, that makes 2029 the earliest realistic approval.
RLS-1496 — the one in this month's headlines
Rubedo Life Sciences, based in Mountain View, California, works on senescent cells — old, damaged cells that stop dividing but don't die, and pump out inflammatory signals that degrade the tissue around them. Its drug, RLS-1496, triggers those cells to self-destruct. It's already in human trials for skin conditions: in an early study for actinic keratosis (sun-damage patches), the first 18 patients saw a 46% drop in lesion count at four weeks versus 11% untreated (Rubedo, May 2026).
The hair news, announced September 16, is earlier than most coverage made it sound. The "first human evidence" is ex vivo: hair follicles taken from balding men, kept alive in a dish and exposed to DHT to mimic the disease. RLS-1496 made them grow longer than untreated follicles over six days, with the top dose "numerically greater" than finasteride — meaning it wasn't statistically tested against it. In animals, it produced about 32% more regrowth than placebo. The first clinical study in people with hair loss starts in October 2026 at a research clinic in Norfolk, Virginia, with initial data expected in the first half of 2027.
ET-02 — "six times more," with eight people per group
Eirion Therapeutics of Woburn, Massachusetts, says its topical ET-02 restores hair follicle stem cells that have stopped working, without touching hormones; it hasn't disclosed exactly how. Its first human trial put 24 men into three groups of eight — placebo, a low dose and a high dose — for four weeks (Eirion, January 2025). The high dose produced "a 6-fold increase in non-vellus hair count compared to the placebo group" at week five; the low dose did very little. That's a ratio of two small changes in eight people each, and no actual hair counts were published. The phase 2 trial, originally planned for 2025, is now expected to start in 2027.
The prolactin antibodies — a second hormone brake
Prolactin, better known for its role in breastfeeding, also acts on hair follicles, and blocking its receptor appears to release a separate brake on growth — step 6 in the diagram. Two companies are testing injected antibodies against it. HMI-115, from China's Hope Medicine, raised hair count by 14 hairs/cm² from baseline in 12 men in a small, open-label Australian study (Hope Medicine, 2024). A placebo-controlled phase 2 in 192 Chinese men finished in August 2024 — and its results have never been released, which is rarely a good sign. ABS-201, from Absci in Vancouver, Washington, is in a phase 1/2a trial in Australia; so far it has shown only safety data, with a half-life long enough for two or three injections over six months, and first hair results due between late 2026 and early 2027 (Absci, August 2026).
So Is Baldness About to Be Cured?
No — and it's worth being precise about why, because the gap between "regrowth" and "full recovery" is where most of the hype lives.
Every trial in this article enrolled men with moderate loss. PP405's big trial takes Norwood IV and V — a receding hairline and a thinning crown with hair still between them. The other trials are similar. Nobody has published a trial in men who have been shiny-bald on top for a decade. There's a hopeful clue in the biology: a University of Pennsylvania team found that bald scalp still contains hair follicle stem cells — what it lacks are the progenitor cells those stem cells should be turning into (Garza, Journal of Clinical Investigation 2011). That's the finding the regenerative companies are building on. Whether any drug can actually restart follicles that have been dormant for years is the question nobody has answered.
The gains are real but partial. The best number in late-stage trials — about 25 extra hairs per square centimetre over placebo for VDPHL01 — is a difference you can see in a mirror and in photos. It is not a return to your hair at 25. And like finasteride and minoxidil, these look like drugs you keep taking: in clascoterone's extension, men who stayed on it did far better than those switched to placebo. Expect a long-term treatment, not a one-off fix.
And timelines slip. Of the companies here, two have already pushed their schedules back by a year or more, and one completed a phase 2 two years ago without releasing results. The realistic calendar: clascoterone and extended-release minoxidil decisions around 2028, PP405 no earlier than 2029, and the cell therapies and senescence drugs later than that — if they work. The genuinely good news is that the pipeline is broader than it has ever been, with at least six different mechanisms in human trials or about to enter them. Some of them will fail. It only takes one or two to succeed.
The Treatments You Can Get This Week
Evidence: Strong for finasteride and minoxidil; moderate to weak for the restHere's the practical reason not to sit and wait for 2028: every drug in the pipeline works best on follicles that are still there. The hair you keep over the next two years is the hair the new drugs will have to work with. And the old treatments are better than their reputation.
Finasteride — still the benchmark
Finasteride 1 mg blocks the enzyme that makes DHT (step 1). In the two pivotal trials, 1,553 men aged 18 to 41 took it or a placebo for a year, and 1,215 carried on into a second year (Kaufman, JAAD 1998). In a one-inch circle on the crown that started with an average of 876 hairs, men on finasteride had 107 more hairs than the placebo group at one year and 138 more at two — while the placebo group kept losing. The FDA label reports the five-year follow-up, and it's the single most useful chart in hair loss:
How men's hair looked after five years, judged from standard photos by an expert panel
Placebo "better" = 6%. Source: Propecia prescribing information (FDA, revised 2022), five-year extension of the 1998 pivotal trials. Hair count difference vs placebo at five years: +277 hairs in the one-inch circle.
Read that as: the main thing finasteride does is stop the decline. Nine in ten men on it were the same or better after five years; three-quarters of men on placebo were visibly worse.
The side effects, honestly. In the 12-month trials, reduced libido occurred in 1.8% of men on finasteride versus 1.3% on placebo, erectile dysfunction in 1.3% versus 0.7%, and ejaculation problems in 1.2% versus 0.7%; 1.2% stopped because of sexual side effects, versus 0.9% on placebo (FDA label). A meta-analysis of the hair-loss trials found the overall increase in sexual dysfunction wasn't statistically significant (Liu, Journal of Sexual Medicine 2016); another, pooling 15 trials, found finasteride raised the risk by about two-thirds, from a low base (Lee, Acta Dermato-Venereologica 2019). The mood question is more serious and less settled: in 2022 the FDA added suicidal thoughts and behaviour to the label's post-marketing section, which already listed depression, and in May 2025 the European Medicines Agency's safety committee confirmed suicidal thoughts as a side effect of finasteride, of unknown frequency, and required a patient card in the pack (EMA, 2025). For most men it's well tolerated; anyone with a history of depression should talk it through with a doctor first, and anyone who notices a change in mood should stop and say so.
Minoxidil — liquid, foam or pill
Topical minoxidil lengthens the growth phase (step 3) and doesn't touch hormones. In a 48-week trial of 393 men, the 5% strength produced 45% more regrowth than 2%, and worked faster, at the cost of more scalp itching (Olsen, JAAD 2002). Low-dose oral minoxidil, prescribed off-label, is the pill alternative. The best head-to-head so far compared 5 mg by mouth with 5% liquid in 90 men for 24 weeks: the pill grew more hair on the crown, but the difference didn't reach statistical significance, and half the men on the pill developed unwanted body hair (Penha, JAMA Dermatology 2024). Lower doses have fewer side effects, and it needs a doctor — it's a blood-pressure drug.
Everything else, ranked
The most useful single comparison is a 2022 network meta-analysis of 23 trials that ranked oral and topical treatments against each other (Gupta, JAMA Dermatology 2022). At 24 weeks, dutasteride 0.5 mg ranked first for total hair count — about 7 hairs/cm² more than finasteride — and 5 mg oral minoxidil ranked first for thick terminal hairs. At 48 weeks, finasteride led (the 5 mg prostate dose for total hairs, the 1 mg hair dose for terminal hairs). Put that together with the individual trials and the evidence lines up like this:
Hair transplants sit outside this list because they're surgery, not treatment: they move follicles from the DHT-resistant back of the head to the front and work well in the right candidate, but they don't stop loss in the hair around them — which is why surgeons usually want patients on finasteride or minoxidil too. And one myth to retire while we're here: creatine doesn't cause hair loss. The rumour came from a 2009 hormone study that never measured hair; a 2025 trial that did found no effect.
A Plan for Every Stage — While You Wait
| Where you are | What the evidence supports | Pipeline drug to watch |
|---|---|---|
| Just noticing temples receding, crown thinning (Norwood II–III) | See a dermatologist to confirm it's pattern loss. Finasteride and/or 5% minoxidil — this is where they work best. Take photos in the same light every six months. | Clascoterone, if you'd rather avoid systemic DHT blockers |
| Clearly thinning Norwood III–V | Finasteride plus minoxidil; ask about oral low-dose minoxidil and microneedling. This is exactly the group the new trials enrol. | VDPHL01, PP405 |
| Worried about finasteride any stage | Minoxidil (topical or oral) alone is a reasonable start; topical finasteride exists but isn't FDA-approved. | Clascoterone, pyrilutamide |
| Bald on top for years Norwood VI–VII | Medication keeps what's left at the sides; a transplant is the only proven way to put hair back on top. Be sceptical of anything promising more. | The regenerative drugs — but nothing has been tested at this stage yet |
This is general information from published trials, not medical advice — finasteride, dutasteride and oral minoxidil are prescription drugs with real side effects, and hair loss that's patchy, sudden or itchy may be something else entirely, like alopecia areata, which has its own newly approved drugs. A dermatologist can tell the difference in a few minutes.
Frequently Asked Questions
Regrowth is coming. Keep what you have until it does.
For thirty years, hair-loss treatment meant two drugs that slow the decline. That's finally changing: a scalp-only DHT blocker and a purpose-built minoxidil pill are closing in on regulators, a stem-cell activator is heading into a 600-man trial, and China, Japan and Korea are running their own programmes. It's the most promising the field has ever looked.
It's also 2028 at the earliest for the first of them, and nobody has shown any of it works on a scalp that's been bald for years. So the best move is the unglamorous one: see a dermatologist, start on what's proven, and take photos. We'll update this page as the trials report — PP405, VDPHL01's second trial and Rubedo's first human data are the three to watch.